|
US5340585A
(en)
|
1991-04-12 |
1994-08-23 |
University Of Southern California |
Method and formulations for use in treating benign gynecological disorders
|
|
TW284688B
(https=)
|
1991-11-20 |
1996-09-01 |
Takeda Pharm Industry Co Ltd |
|
|
FR2710637B1
(fr)
|
1993-09-28 |
1995-12-08 |
Roquette Freres |
Mannitol pulvérulent de friabilité modérée et son procédé de préparation.
|
|
JP3854648B2
(ja)
|
1994-04-19 |
2006-12-06 |
武田薬品工業株式会社 |
縮合チオフェン誘導体、その製造法及び用途
|
|
ECSP961635A
(es)
|
1996-01-11 |
1997-06-27 |
|
Desprendimiento controlado de esteroides del recubrimiento de azucar
|
|
ECSP971998A
(es)
|
1997-01-15 |
1998-04-07 |
|
Desprendimiento controlado de esteroides del recubrimiento de azucar
|
|
DE19815060A1
(de)
|
1998-04-03 |
1999-10-14 |
Jenapharm Gmbh |
Pharmazeutische Präparate zur Therapie von Nebenwirkungen während und/oder nach einer GnRHa-Therapie
|
|
US6265393B1
(en)
|
1998-08-07 |
2001-07-24 |
Heinrichs William Leroy |
Prevention of endometriosis signs or symptons
|
|
RU2233284C2
(ru)
|
1999-03-24 |
2004-07-27 |
Такеда Кемикал Индастриз, Лтд. |
Тиенопиримидиновые производные, способ их получения, фармацевтическая композиция и способ антагонизации гонадотропин-рилизинг гормона
|
|
TWI225863B
(en)
|
1999-03-24 |
2005-01-01 |
Takeda Chemical Industries Ltd |
Thienopyrimidine compounds, their production and use
|
|
KR20030005205A
(ko)
|
2000-02-29 |
2003-01-17 |
다케다 야쿠힌 고교 가부시키가이샤 |
티에노피리미딘 유도체의 제조 방법
|
|
JP5072166B2
(ja)
|
2002-01-30 |
2012-11-14 |
武田薬品工業株式会社 |
チエノピリミジン化合物、その製造法および用途
|
|
US7569570B2
(en)
|
2002-01-30 |
2009-08-04 |
Takeda Pharmaceutical Company Limited |
Thienopyrimidines, process for preparing the same and use thereof
|
|
BRPI0307786B8
(pt)
|
2002-02-26 |
2021-05-25 |
Astrazeneca Ab |
composição farmacêutica, método para preparar a mesma, métodos para inibir a taxa de precipitação do agente da solução no trato gi, e para reduzir variabilidade inter-pacientes no que se refere à biodisponibilidade e/ou concentrações plásmáticas do agente, e, uso de um celulose éter solúvel em água ou de um éster de um celulose éter solúvel em água
|
|
EP1591446B1
(en)
|
2003-01-29 |
2013-03-06 |
Takeda Pharmaceutical Company Limited |
Thienopyrimidine compounds and use thereof
|
|
JP4039574B2
(ja)
|
2003-01-29 |
2008-01-30 |
武田薬品工業株式会社 |
チエノピリミジン化合物およびその用途
|
|
PE20130200A1
(es)
|
2003-04-08 |
2013-03-09 |
Novartis Ag |
Composicion farmaceutica que contiene un agonista del receptor s1p y un alcohol de azucar
|
|
AU2004257639B2
(en)
|
2003-07-07 |
2011-01-06 |
Neurocrine Biosciences, Inc. |
Pyrimidine-2, 4-dione derivatives as gonadotropin-releasing hormone receptor antagonists
|
|
MY151322A
(en)
|
2004-04-30 |
2014-05-15 |
Bayer Ip Gmbh |
Management of breakthrough bleeding in extended hormonal contraceptive regimens
|
|
KR20080041662A
(ko)
|
2005-07-22 |
2008-05-13 |
다케다 야쿠힌 고교 가부시키가이샤 |
조기 배란 예방제
|
|
AR058584A1
(es)
|
2005-12-22 |
2008-02-13 |
Takeda Pharmaceutical |
Derivados de metastina y uso de los mismos
|
|
EP2155194B1
(en)
|
2007-04-06 |
2015-01-21 |
Neurocrine Biosciences, Inc. |
Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
|
|
US8765948B2
(en)
|
2007-11-07 |
2014-07-01 |
Neurocrine Biosciences, Inc. |
Processes for the preparation of uracil derivatives
|
|
EP2329823A4
(en)
|
2008-09-03 |
2013-04-03 |
Takeda Pharmaceutical |
PROCESS FOR INCREASING THE ABSORPTION ABILITY OF A PREPARATION AND PREPARATION WITH INCREASED ABSORPTION ABILITY
|
|
US9427418B2
(en)
|
2009-02-23 |
2016-08-30 |
Gtx, Inc. |
Estrogen receptor ligands and methods of use thereof
|
|
US9624161B2
(en)
|
2009-02-23 |
2017-04-18 |
Gtx, Inc. |
Estrogen receptor ligands and methods of use thereof
|
|
EA026675B1
(ru)
|
2010-06-16 |
2017-05-31 |
Эндорешерш, Инк. |
Способы лечения или предотвращения эстрогензависимых заболеваний
|
|
JP2012077020A
(ja)
|
2010-09-30 |
2012-04-19 |
Mochida Pharmaceut Co Ltd |
ゲスターゲンとＧｎＲＨアンタゴニストとの組合せ医薬
|
|
PL2900675T3
(pl)
|
2012-09-28 |
2019-08-30 |
Takeda Pharmaceutical Company Limited |
Sposób wytwarzania pochodnej tienopirymidyny
|
|
PL2945628T3
(pl)
|
2013-01-15 |
2020-09-21 |
Aragon Pharmaceuticals, Inc. |
Modulator receptorów androgenowych w skojarzeniu z octanem abirateronu i prednizonem do leczenia nowotworu stercza
|
|
IL241595B2
(en)
|
2013-03-15 |
2025-10-01 |
Abbvie Inc |
Composition for use in methods of treating heavy menstrual bleeding associated with uterine fibroids
|
|
CA2978223A1
(en)
|
2015-02-26 |
2016-09-01 |
Takeda Pharmaceutical Company Limited |
Formulations of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethyl amino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
|
|
US9949974B2
(en)
|
2015-09-01 |
2018-04-24 |
Abbvie Inc. |
Methods of adminstering elagolix
|
|
EP3518933B2
(en)
|
2016-09-30 |
2025-02-26 |
Sumitomo Pharma Switzerland GmbH |
Methods of treating uterine fibroids and endometriosis
|
|
CN110248661A
(zh)
|
2016-09-30 |
2019-09-17 |
梦欧文科学有限责任公司 |
前列腺癌的治疗
|
|
SG11201911598WA
(en)
|
2017-06-05 |
2020-01-30 |
ObsEva SA |
Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
|
|
SG11202104053TA
(en)
*
|
2018-11-07 |
2021-05-28 |
ObsEva SA |
Compositions and methods for the treatment of estrogen-dependent disorders
|
|
JP2022551316A
(ja)
|
2019-10-10 |
2022-12-08 |
ミオバント サイエンシズ ゲーエムベーハー |
Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形
|
|
EP4041738A1
(en)
|
2019-10-10 |
2022-08-17 |
Myovant Sciences GmbH |
Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
|
|
BR112022023937A2
(pt)
|
2020-05-29 |
2022-12-27 |
Myovant Sciences Gmbh |
Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina
|
|
EP4243829A1
(en)
|
2020-11-11 |
2023-09-20 |
Myovant Sciences GmbH |
Methods of administering relugolix
|
|
WO2023066941A1
(en)
|
2021-10-18 |
2023-04-27 |
Myovant Sciences Gmbh |
Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
|